Degenerative disc disease can lead to multiple disorders, such as spondylolisthesis, retrospondylolisthesis and lumbar spinal stenosis. Approximately 90% of people witness an episode of debilitating back pain at a later point in their lives. Biopharmaceutical companies are currently targeting oral treatment and peripherally acting analgesics.
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Artificial Disc Replacement, Cervical Spine, Lumbar Spine, Thoracic Spine, Spinal Fusion), End- Users (Hospitals, Clinics, Others), Product Type (ALLOB, AMG-0101, BRTX-100, OTICR-01, Others) – Industry Trends and Forecast to 2032
.
The Global Degenerative Disk Disease Market size was valued at USD 1.62 USD Billion in 2024.
The Global Degenerative Disk Disease Market is projected to grow at a CAGR of 3.6% during the forecast period of 2025 to 2032.
The major players operating in the market include B. Braun Melsungen AG, AxioMed LLC, Medical Devices Business Services , Zimmer Biomet Spine , Biomet, Medtronic, Stryker, Ensol Biosciences , U.S. Stem Cell , Kolon TissueGene , Samumed LLC, BIOPHARM GmbH, SpineVision, Sarl COUSIN BIOTECH, Globus Medical, Paradigm Spine LLC.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
